120 related articles for article (PubMed ID: 17141530)
21. Analysis of protein-ligand interactions by fluorescence polarization.
Rossi AM; Taylor CW
Nat Protoc; 2011 Mar; 6(3):365-87. PubMed ID: 21372817
[TBL] [Abstract][Full Text] [Related]
22. Zebrafish: an emerging technology for in vivo pharmacological assessment to identify potential safety liabilities in early drug discovery.
Barros TP; Alderton WK; Reynolds HM; Roach AG; Berghmans S
Br J Pharmacol; 2008 Aug; 154(7):1400-13. PubMed ID: 18552866
[TBL] [Abstract][Full Text] [Related]
23. Structural Alterations of the "Address" Moiety of NAN Leading to the Discovery of a Novel Opioid Receptor Modulator with Reduced hERG Toxicity.
Ma H; Pagare PP; Li M; Neel LT; Mendez RE; Gillespie JC; Stevens DL; Dewey WL; Selley DE; Zhang Y
J Med Chem; 2023 Jan; 66(1):577-595. PubMed ID: 36538027
[TBL] [Abstract][Full Text] [Related]
24. Investigation of Cardiovascular Effects of Tetrahydro-β-carboline sstr3 antagonists.
He S; Lai Z; Ye Z; Dobbelaar PH; Shah SK; Truong Q; Du W; Guo L; Liu J; Jian T; Qi H; Bakshi RK; Hong Q; Dellureficio J; Reibarkh M; Samuel K; Reddy VB; Mitelman S; Tong SX; Chicchi GG; Tsao KL; Trusca D; Wu M; Shao Q; Trujillo ME; Fernandez G; Nelson D; Bunting P; Kerr J; Fitzgerald P; Morissette P; Volksdorf S; Eiermann GJ; Li C; Zhang B; Howard AD; Zhou YP; Nargund RP; Hagmann WK
ACS Med Chem Lett; 2014 Jul; 5(7):748-53. PubMed ID: 25050159
[TBL] [Abstract][Full Text] [Related]
25. Safety pharmacology in 2022: Taking one small step for cardiovascular safety assay development but one giant leap for regulatory drug safety assessment.
Pugsley MK; Koshman YE; de Korte T; Authier S; Winters BR; Curtis MJ
J Pharmacol Toxicol Methods; 2022; 117():107206. PubMed ID: 35926772
[TBL] [Abstract][Full Text] [Related]
26. Fluorescence based HTS-compatible ligand binding assays for dopamine D
Tahk MJ; Laasfeld T; Meriste E; Brea J; Loza MI; Majellaro M; Contino M; Sotelo E; Rinken A
Front Mol Biosci; 2023; 10():1119157. PubMed ID: 37006609
[TBL] [Abstract][Full Text] [Related]
27. Fluorescence polarization assays in small molecule screening.
Lea WA; Simeonov A
Expert Opin Drug Discov; 2011 Jan; 6(1):17-32. PubMed ID: 22328899
[TBL] [Abstract][Full Text] [Related]
28. An Optimized Microscale Thermophoresis Method for High-Throughput Screening of DNA Methyltransferase 2 Ligands.
Zimmermann RA; Schwickert M; Meidner JL; Nidoieva Z; Helm M; Schirmeister T
ACS Pharmacol Transl Sci; 2022 Nov; 5(11):1079-1085. PubMed ID: 36407957
[TBL] [Abstract][Full Text] [Related]
29. The open-access dataset for insilico cardiotoxicity prediction system.
Polak S; Wisniowska B; Fijorek K; Glinka A; Polak M; Mendyk A
Bioinformation; 2011; 6(6):244-5. PubMed ID: 21738323
[TBL] [Abstract][Full Text] [Related]
30. Fluorescently labeled analogues of dofetilide as high-affinity fluorescence polarization ligands for the human ether-a-go-go-related gene (hERG) channel.
Singleton DH; Boyd H; Steidl-Nichols JV; Deacon M; Groot MJ; Price D; Nettleton DO; Wallace NK; Troutman MD; Williams C; Boyd JG
J Med Chem; 2007 Jun; 50(13):2931-41. PubMed ID: 17536794
[TBL] [Abstract][Full Text] [Related]
31. Development of the predictor HERG fluorescence polarization assay using a membrane protein enrichment approach.
Piper DR; Duff SR; Eliason HC; Frazee WJ; Frey EA; Fuerstenau-Sharp M; Jachec C; Marks BD; Pollok BA; Shekhani MS; Thompson DV; Whitney P; Vogel KW; Hess SD
Assay Drug Dev Technol; 2008 Apr; 6(2):213-23. PubMed ID: 18471075
[TBL] [Abstract][Full Text] [Related]
32. Evolution of strategies to improve preclinical cardiac safety testing.
Gintant G; Sager PT; Stockbridge N
Nat Rev Drug Discov; 2016 Jul; 15(7):457-71. PubMed ID: 26893184
[TBL] [Abstract][Full Text] [Related]
33. Investigation of miscellaneous hERG inhibition in large diverse compound collection using automated patch-clamp assay.
Yu HB; Zou BY; Wang XL; Li M
Acta Pharmacol Sin; 2016 Jan; 37(1):111-23. PubMed ID: 26725739
[TBL] [Abstract][Full Text] [Related]
34. High throughput screening technologies for ion channels.
Yu HB; Li M; Wang WP; Wang XL
Acta Pharmacol Sin; 2016 Jan; 37(1):34-43. PubMed ID: 26657056
[TBL] [Abstract][Full Text] [Related]
35. Biomimetic membrane platform containing hERG potassium channel and its application to drug screening.
Arslan Yildiz A; Kang C; Sinner EK
Analyst; 2013 Apr; 138(7):2007-12. PubMed ID: 23423263
[TBL] [Abstract][Full Text] [Related]
36. Development of BODIPY FL VH032 as a High-Affinity and Selective von Hippel-Lindau E3 Ligase Fluorescent Probe and Its Application in a Time-Resolved Fluorescence Resonance Energy-Transfer Assay.
Lin W; Li Y; Yang L; Chen T
ACS Omega; 2021 Jan; 6(1):680-695. PubMed ID: 33458521
[TBL] [Abstract][Full Text] [Related]
37. Discovery and in Vitro Optimization of 3-Sulfamoylbenzamides as ROMK Inhibitors.
Sammons MF; Kharade SV; Filipski KJ; Boehm M; Smith AC; Shavnya A; Fernando DP; Dowling MS; Carpino PA; Castle NA; Zellmer SG; Antonio BM; Gosset JR; Carlo A; Denton JS
ACS Med Chem Lett; 2018 Feb; 9(2):125-130. PubMed ID: 29456800
[TBL] [Abstract][Full Text] [Related]
38. Computational Tool for Fast
Chemi G; Gemma S; Campiani G; Brogi S; Butini S; Brindisi M
Front Chem; 2017; 5():7. PubMed ID: 28503546
[TBL] [Abstract][Full Text] [Related]
39. Natural products modulating the hERG channel: heartaches and hope.
Kratz JM; Grienke U; Scheel O; Mann SA; Rollinger JM
Nat Prod Rep; 2017 Aug; 34(8):957-980. PubMed ID: 28497823
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
